AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21419704 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV2‐GAD infusions
Number of subjects: 66
Study 21419704 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 66
Study 19641312 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal
Number of subjects: 30
Study 19641312 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 30
Study 17317676 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib treatment
Number of subjects: 25
Study 15851147 — intervention group
Group type: EXPERIMENTAL
Intervention: MVP
Number of subjects: 30
Study 15851147 — intervention group
Group type: COMPARATOR
Intervention: DDD/R
Number of subjects: 30
Study 11231767 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser transscleral cyclophotocoagulation (TSCPC) at 1.5 W for 1.5 seconds
Number of subjects: 92
Study 11231767 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser transscleral cyclophotocoagulation (TSCPC) at 1.25 W for 2.5 seconds
Number of subjects: 92
Study 9771860 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 IU GH twice daily from 2 days before to 7 days after the operation
Number of subjects: 24
Study 9771860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7819101 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin‐10 (IL‐10)
Number of subjects: 105
Study 7819101 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble interleukin‐2 receptor (sIL‐2r)
Number of subjects: 105
Study 7819101 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of elevated IL‐10 and sIL‐2r > 3000 U/ml
Number of subjects: 105
Study 7819101 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IL‐10 with sIL‐2r
Number of subjects: 105
Study 3046294 — intervention group
Group type: EXPERIMENTAL
Intervention: intravenous anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 240
Study 3046294 — intervention group
Group type: COMPARATOR
Intervention: intracoronary streptokinase
Number of subjects: 240
Study 29746177 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative advertising
Number of subjects: 305
Study 29746177 — intervention group
Group type: EXPERIMENTAL
Intervention: Role Transportation Theory in advertising
Number of subjects: 305
Study 29746177 — intervention group
Group type: EXPERIMENTAL
Intervention: Role transference
Number of subjects: 305
Study 29746177 — intervention group
Group type: EXPERIMENTAL
Intervention: Truth avoidance
Number of subjects: 305
Study 29746177 — intervention group
Group type: COMPARATOR
Intervention: Informative advertising
Number of subjects: 305
Study 28500373 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (VAR)
Number of subjects: 110
Study 28500373 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 110
Study 25144403 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational multimedia intervention
Number of subjects: 90
Study 25144403 — intervention group
Group type: EXPERIMENTAL
Intervention: Entertainment video game intervention
Number of subjects: 90
Study 25144403 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 24206873 — intervention group
Group type: EXPERIMENTAL
Intervention: DCB (3 μg/mm²) followed by CoCr-stent
Number of subjects: 97
Study 24206873 — intervention group
Group type: COMPARATOR
Intervention: Stent first followed by DCB
Number of subjects: 97
Study 20847736 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA with self-monitoring software and daily feedback messages (PDA+FB)
Number of subjects: 210
Study 20847736 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA with self-monitoring software
Number of subjects: 210
Study 20847736 — intervention group
Group type: COMPARATOR
Intervention: Paper diary/record (PR)
Number of subjects: 210
Study 20847736 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA groups
Number of subjects: 210
Study 18082667 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mcg of vaginal misoprostol every 6 h up to four doses
Number of subjects: 210
Study 18082667 — intervention group
Group type: COMPARATOR
Intervention: 400 mcg of vaginal misoprostol every 4 h up to five doses
Number of subjects: 210
Study 16678205 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg BID
Number of subjects: 87
Study 16678205 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD (after switching from placebo)
Number of subjects: 87
Study 16678205 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD
Number of subjects: 87
Study 16678205 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 87
Study 12946551 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.1% ophthalmic solution
Number of subjects: 107
Study 12946551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 12946551 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 107
Study 11076429 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral granisetron plus i.v. dexamethasone
Number of subjects: 51
Study 11076429 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ondansetron plus i.v. dexamethasone
Number of subjects: 51
Study 9084348 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate, 800 mg orally, once per day for 2 weeks of 15 weeks, repeated once.
Number of subjects: 13
Study 9084348 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (without etidronate).
Number of subjects: 13
Study 8210923 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg etodolac SR once a day for up to 52 weeks
Number of subjects: 539
Study 8210923 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg etodolac SR once a day for up to 52 weeks
Number of subjects: 539
Study 8210923 — intervention group
Group type: EXPERIMENTAL
Intervention: etodolac SR
Number of subjects: 539
Study 3730528 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg innovator product
Number of subjects: 0
Study 3730528 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg generic product
Number of subjects: 0
Study 3730528 — intervention group
Group type: COMPARATOR
Intervention: 50 mg solution
Number of subjects: 0
Study 3730528 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine (all products)
Number of subjects: 0
Study 3730528 — intervention group
Group type: EXPERIMENTAL
Intervention: All products
Number of subjects: 0
Study 31954696 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 50
Study 31954696 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback
Number of subjects: 50
Study 29757462 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 g guava/day
Number of subjects: 0
Study 29757462 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg synthetic vitamin C/day
Number of subjects: 0
Study 29757462 — intervention group
Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 0
Study 27424313 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of n-3 FA 2 g + fenofibrate 160 mg
Number of subjects: 50
Study 27424313 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg
Number of subjects: 50
Study 27424313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 27424313 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of n-3 FA + fenofibrate
Number of subjects: 50
Study 27424313 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 50
Study 25210025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 6351
Study 25210025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6351
Study 23428122 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA treatment (25-30 mg/kg•d)
Number of subjects: 75
Study 23428122 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment for asthma
Number of subjects: 75
Study 27534055 — intervention group
Group type: EXPERIMENTAL
Intervention: Affinoleukine (AFL)
Number of subjects: 23
Study 27534055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AFL)
Number of subjects: 23
Study 17971511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (30 microg)
Number of subjects: 14
Study 17971511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15772920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical care delivered by a nurse practitioner and a nephrologist
Number of subjects: 800
Study 15772920 — intervention group
Group type: COMPARATOR
Intervention: Care provided by the nephrologist alone
Number of subjects: 800
Study 12670780 — intervention group
Group type: EXPERIMENTAL
Intervention: montelukast 10mg daily
Number of subjects: 51
Study 12670780 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide 400 microg twice a day (bid)
Number of subjects: 51
Study 12670780 — intervention group
Group type: EXPERIMENTAL
Intervention: montelukast 10 mg daily plus budesonide 400 microg bid
Number of subjects: 51
Study 12670780 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide 800 microg bid
Number of subjects: 51
Study 11910586 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol in 1 g gel daily + 10 mg medroxyprogesterone acetate for the first 12 days every month (Group I)
Number of subjects: 395
Study 11910586 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol in 1 g gel daily + 10 mg medroxyprogesterone acetate for the first 12 days every 3 months (Group II)
Number of subjects: 395
Study 11910586 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol in 1 g gel daily + 10 mg medroxyprogesterone acetate for the first 12 days every month (Group III)
Number of subjects: 395
Study 11910586 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial safety assessment
Number of subjects: 395
Study 11910586 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptability of the gel
Number of subjects: 395
Study 8994285 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy
Number of subjects: 43
Study 8994285 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 43
Study 8994285 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt
Number of subjects: 43
Study 1473437 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g 5‐ASA foam
Number of subjects: 10
Study 1473437 — intervention group
Group type: COMPARATOR
Intervention: 4 g 5‐ASA enema
Number of subjects: 10
Study 6237836 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine (Z), 200 mg by mouth, preceded by 1 hr and followed for 7 hr of oral ethanol (E) in juice dosed to maintain blood alcohol concentrations between 800 and 1000 mg/l
Number of subjects: 6
Study 6237836 — intervention group
Group type: COMPARATOR
Intervention: Placebo Z and E
Number of subjects: 6
Study 6237836 — intervention group
Group type: EXPERIMENTAL
Intervention: Z and juice
Number of subjects: 6
Study 6237836 — intervention group
Group type: COMPARATOR
Intervention: Placebo Z and juice
Number of subjects: 6
Study 6237836 — intervention group
Group type: COMPARATOR
Intervention: E
Number of subjects: 6
Study 30657249 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation (exercise counselling session followed by a 13-17 week telephone-guided walking programme)
Number of subjects: 78
Study 30657249 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 78
Study 28138381 — intervention group
Group type: EXPERIMENTAL
Intervention: d-Cycloserine (DCS) 50 mg administered 30 min prior to group social skills training
Number of subjects: 60
Study 28138381 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 30 min prior to group social skills training
Number of subjects: 60
Study 27703725 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly extended release exenatide for 24 weeks
Number of subjects: 60
Study 27703725 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60
Study 24326981 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of vitamin E plus 400 mg of vitamin C
Number of subjects: 256
Study 24326981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 21890277 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (300 mg)
Number of subjects: 28
Study 21890277 — intervention group
Group type: COMPARATOR
Intervention: Control group (never depressed women)
Number of subjects: 28
Study 19576915 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic load (HG) diet
Number of subjects: 42
Study 19576915 — intervention group
Group type: COMPARATOR
Intervention: Low glycemic load (LG) diet
Number of subjects: 42
Study 17727580 — intervention group
Group type: EXPERIMENTAL
Intervention: IV(2) flow medical device
Number of subjects: 52
Study 17727580 — intervention group
Group type: COMPARATOR
Intervention: Standard gravitational infusion sets without IV(2) flow
Number of subjects: 52
Study 15077078 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone plus metoprolol
Number of subjects: 253
Study 15077078 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 253
Study 15077078 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 253
Study 15077078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 15685462 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee joint effusion (experimental condition)
Number of subjects: 8
Study 15685462 — intervention group
Group type: COMPARATOR
Intervention: Control condition (saline injection)
Number of subjects: 8
Study 10500939 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam premedication group (group D(+), n = 14)
Number of subjects: 28
Study 10500939 — intervention group
Group type: COMPARATOR
Intervention: No premedication group (group D(-), n = 14)
Number of subjects: 28
Study 8561329 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 15 micrograms
Number of subjects: 15
Study 8561329 — intervention group
Group type: COMPARATOR
Intervention: Contraction-associated tachycardic responses (CATRs)
Number of subjects: 15
Study 1895369 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine (10 mg)
Number of subjects: 9
Study 1895369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6282926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IGIV), 5%, in 10% maltose, administered at a dose of 20 cc/kg
Number of subjects: 0
Study 6282926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IGIV), 5%, in 10% maltose, at doses lower than 20 cc/kg
Number of subjects: 0
Study 6282926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IGIV) administered at 20 cc/kg once every week (currently under evaluation)
Number of subjects: 0
Study 6282926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IGIV)
Number of subjects: 0
Study 6282926 — intervention group
Group type: COMPARATOR
Intervention: CMV immune plasma (for comparison)
Number of subjects: 0
Study 30666966 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐L low‐volume bowel preparation regimen
Number of subjects: 200
Study 30666966 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐L high‐volume bowel preparation regimen
Number of subjects: 200
Study 30666966 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection group (RG) with left colon resection
Number of subjects: 200
Study 30666966 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐volume preparation
Number of subjects: 200
Study 30666966 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 30247951 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 63
Study 30247951 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 63
Study 27079196 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 20
Study 27079196 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS-based DTI FT
Number of subjects: 20
Study 27079196 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS combined with rTMS-based DTI FT
Number of subjects: 20
Study 27079196 — intervention group
Group type: COMPARATOR
Intervention: DCS
Number of subjects: 20
Study 25103182 — intervention group
Group type: EXPERIMENTAL
Intervention: AWARE intervention (30-minute patient education)
Number of subjects: 67
Study 25103182 — intervention group
Group type: COMPARATOR
Intervention: Routine care only (control group)
Number of subjects: 67
Study 22130104 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg
Number of subjects: 46
Study 22130104 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg
Number of subjects: 46
Study 22130104 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 60 mg
Number of subjects: 46
Study 22130104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 21153945 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing-implemented sedation protocol (Group N, n=25)
Number of subjects: 50
Study 21153945 — intervention group
Group type: COMPARATOR
Intervention: Daily interruption of sedative infusion (Group P, n=25)
Number of subjects: 50
Study 18187432 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole bean soy milk
Number of subjects: 28
Study 18187432 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate milk
Number of subjects: 28
Study 18187432 — intervention group
Group type: COMPARATOR
Intervention: Dairy milk
Number of subjects: 28
Study 15786484 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy plus family intervention
Number of subjects: 92
Study 15786484 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 92
Study 11903077 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming mattress (Group M)
Number of subjects: 59
Study 11903077 — intervention group
Group type: COMPARATOR
Intervention: Active i.v. fluid tube warming system (Group T)
Number of subjects: 59
Study 10443214 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable covered metal Wallstent
Number of subjects: 40
Study 10443214 — intervention group
Group type: COMPARATOR
Intervention: Plastic Procter Livingstone tube
Number of subjects: 40
Study 7797776 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-glucose infusion followed by multidose subcutaneous insulin for > or = 3 months
Number of subjects: 620
Study 7797776 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 620
Study 31968396 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (n = 40)
Number of subjects: 78
Study 31968396 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 78
Study 31968396 — intervention group
Group type: COMPARATOR
Intervention: Moderately high-protein diet (n = 38)
Number of subjects: 78
Study 31347332 — intervention group
Group type: EXPERIMENTAL
Intervention: MRgFUS thalamotomy with SDR above 0.4
Number of subjects: 50
Study 31347332 — intervention group
Group type: EXPERIMENTAL
Intervention: MRgFUS thalamotomy with SDR above 0.45
Number of subjects: 50
Study 31347332 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 50
Study 27930952 — intervention group
Group type: EXPERIMENTAL
Intervention: Food addiction symptoms
Number of subjects: 178
Study 25847555 — intervention group
Group type: EXPERIMENTAL
Intervention: Tango classes (N=18)
Number of subjects: 40
Study 23611569 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 10, 20, 40, 60, and 80 mg/day
Number of subjects: 100
Study 23611569 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 100
Study 23611569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23611569 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 100
Study 21950147 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (delayed release divalproex sodium)
Number of subjects: 0
Study 21950147 — intervention group
Group type: COMPARATOR
Intervention: Reference product (delayed release divalproex sodium)
Number of subjects: 0
Study 21950147 — intervention group
Group type: COMPARATOR
Intervention: Comparison of test and reference products
Number of subjects: 0
Study 17660177 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1 microg/kg combined with propofol 1 mg/kg
Number of subjects: 60
Study 17660177 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil 0.1 microg/kg combined with midazolam 0.05 mg/kg
Number of subjects: 60
Study 16101707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 microg.kg(‐1) IV
Number of subjects: 60
Study 16101707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11833836 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinafloxacin 200 mg IV every 12 hours
Number of subjects: 84
Study 11833836 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/tazobactam 3.375 g IV every 6 hours
Number of subjects: 84
Study 10511931 — intervention group
Group type: EXPERIMENTAL
Intervention: AK incisions with collagen implants
Number of subjects: 8
Study 10511931 — intervention group
Group type: COMPARATOR
Intervention: AK incisions without collagen implants (Control)
Number of subjects: 8
Study 7856671 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy (10 L/min by face mask)
Number of subjects: 86
Study 7856671 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy for ≤ 10 minutes
Number of subjects: 86
Study 7856671 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy for > 10 minutes
Number of subjects: 86
Study 7856671 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study 1950214 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose antibiotic prophylaxis
Number of subjects: 0
Study 1950214 — intervention group
Group type: COMPARATOR
Intervention: Control group without antibiotic prophylaxis
Number of subjects: 0
Study 7042092 — intervention group
Group type: EXPERIMENTAL
Intervention: IF radiotherapy plus MOPP chemotherapy
Number of subjects: 305
Study 7042092 — intervention group
Group type: COMPARATOR
Intervention: EF radiotherapy
Number of subjects: 305